Pharmaceuticals: Positive phase III results for Lilly's SGLT-2 inhibitor, Jardiance. Implications for our stock universe

News published on August Friday 21, 2015
Share on

Eli Lilly and Boehringer announced that their SGLT-2 inhibitor, Jardiance (in combination with a DPP-4 inhibitor), reduced the CV risks in patients suffering from Type 2 Diabetes. We think this is good news for the whole therapeutic class. If we should retain a winner then this would be AstraZeneca given its leading position outside the US. On the other hand, companies that only have GLP-1 analogues or DPP-4 in their portfolio, like Novo Nordisk, Novartis, and, to a lesser extent, Sanofi, may suffer from this evolving paradigm.


For more indormation please contact marketing@bryangarnier.com  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities